Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer

References

• American Cancer SocietyCancer Facts and Figures 2012AtlantaAmerican Cancer Society2012
   Google Scholar
• GermanoSO’DriscollLBreast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicineCurr Cancer Drug Targets20099339841819442059
   PubMed Web of Science ®Google Scholar
• VivancoISawyersCLThe phosphatidylinositol 3-kinase AKT pathway in human cancerNat Rev Cance200227489501
   PubMed Web of Science ®Google Scholar
• WoodLDParsonsDWJonesSThe genomic landscapes of human breast and colorectal cancersScience200731858531108111317932254
   PubMed Web of Science ®Google Scholar
• CuiXZhangPDengWInsulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancerMol Endocrinol200317457558812554765
   PubMed Web of Science ®Google Scholar
• ZhouBPHuMCMillerSAHER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathwayJ Biol Chem2000275118027803110713122
   PubMed Web of Science ®Google Scholar
• Stemke-HaleKGonzalez-AnguloAMLluchAAn integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancerCancer Res200868156084609118676830
   PubMed Web of Science ®Google Scholar
• WullschlegerSLoewithRHallMNTOR signaling in growth and metabolismCell2006124347148416469695
   PubMed Web of Science ®Google Scholar
• GuertinDASabatiniDMDefining the role of mTOR in cancerCancer Cell200712192217613433
   PubMed Web of Science ®Google Scholar
• Perez-TenorioGAlkhoriLOlssonBPIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancerClin Cancer Res200713123577358417575221
   PubMed Web of Science ®Google Scholar
• KarakasBBachmanKEParkBHMutation of the PIK3CA oncogene in human cancersBr J Cancer200694445545916449998
   PubMed Web of Science ®Google Scholar
• deGraffenriedLAFriedrichsWERussellDHInhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt ActivityClin Cancer Res200410238059806715585641
   PubMed Web of Science ®Google Scholar
• MusgroveEASutherlandRLBiological determinants of endocrine resistance in breast cancerNat Rev Cancer20099963164319701242
   PubMed Web of Science ®Google Scholar
• CholletPAbrialCTaccaOMammalian target of rapamycin inhibitors in combination with letrozole in breast cancerClin Breast Cancer20067433633817092402
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• KataokaYMukoharaTShimadaHSaijoNHiraiMMinamiHAssociation between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell linesAnn Oncol201021225526219633047
   PubMed Web of Science ®Google Scholar
• BjornstiMAHoughtonPJThe TOR pathway: a target for cancer therapyNat Rev Cancer20044533534815122205
   PubMed Web of Science ®Google Scholar
• CampbellRABhat-NakshatriPPatelNMConstantinidouDAliSNakshatriHPhosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistanceJ Biol Chem2001276139817982411139588
   PubMed Web of Science ®Google Scholar
• DeGraffenriedLFriedrichsWFulcherLThe mTOR inhibitor CCI-779 restores tamoxifen response in breast cancer cells with high Akt activity. Proceedings of the 14th NCI-EORTC-AACR Symposium on Molecular Targets and Cancer TherapeuticsEur J Cancer2002S158
   Web of Science ®Google Scholar
• SmithCLCross-talk between peptide growth factor and estrogen receptor signaling pathwaysBiol Reprod19985836276329510949
   PubMed Web of Science ®Google Scholar
• BoulayARudloffJYeJDual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancerClin Cancer Res200511145319532816033851
   PubMed Web of Science ®Google Scholar
• TreeckOWackwitzBHausUOrtmannOEffects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cellsGynecol Oncol2006102229229916443261
   PubMed Web of Science ®Google Scholar
• BeeramMTanQTTekmalRRRussellDMiddletonADeGraffenriedLAAkt-induced endocrine therapy resistance is reversed by inhibition of mTOR signalingAnn Oncol20071881323132817693645
   PubMed Web of Science ®Google Scholar
• CarpenterJTRochéHCamponeMRandomized 3-arm, Phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol 2005 ASCO Annual Meeting Proceedings23Suppl 16 Part I of II (June 1 Suppl), 2005564
   Web of Science ®Google Scholar
• WolffACLazarAABondarenkoIRandomized Phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancerJ Clin Oncol201331219520223233719
   PubMed Web of Science ®Google Scholar
• KirchnerGIMeier-WiedenbachIMannsMPClinical pharmacokinetics of everolimusClin Pharmacokinet2004432839514748618
   PubMed Web of Science ®Google Scholar
• AwadaACardosoFFontaineCThe oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokineticsEur J Cancer2008441849118039566
   PubMed Web of Science ®Google Scholar
• BaselgaJSemiglazovVvan DamPPhase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancerJ Clin Oncol200927162630263719380449
   PubMed Web of Science ®Google Scholar
• SabineVSSimsAHMacaskillEJGene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancerBreast Cancer Res Treat2010122241942820480226
   PubMed Web of Science ®Google Scholar
• BachelotTBourgierCCropetCRandomized Phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO studyJ Clin Oncol201230222718272422565002
   PubMed Web of Science ®Google Scholar
• BaselgaJCamponeMPiccartMEverolimus in postmenopausal hormone-receptor-positive advanced breast cancerN Engl J Med2012366652052922149876
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
   PubMed Web of Science ®Google Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• HarariDYardenYMolecular mechanisms underlying ErbB2/HER2 action in breast cancerOncogene200019536102611411156523
   PubMed Web of Science ®Google Scholar
• LuCHWyszomierskiSLTsengLMPreclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiencyClin Cancer Res200713195883588817908983
   PubMed Web of Science ®Google Scholar
• AndreFCamponeMO’ReganRPhase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumabJ Clin Oncol201028345110511520975068
   PubMed Web of Science ®Google Scholar
• DalencFCamponeMHupperetsPEverolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trialProceedings of the American Society of Clinical Oncology Annual MeetingJune 4–8, 2010Chicago, IL, USA
   Google Scholar
• JerusalemGFasoloADierasVPhase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancerBreast Cancer Res Treat2011125244745521107682
   PubMed Web of Science ®Google Scholar
• CamponeMGianniLMassacesiCTrastuzumab and everolimus (RAD001) containing regimens are safe and active when reintroduced in patients with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib [abstract]Eur J Cancer Suppl20108186
   Web of Science ®Google Scholar
• MorrowPKWulfGMEnsorJPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapyJ Clin Oncol201129233126313221730275
   PubMed Web of Science ®Google Scholar
• Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1) Available from http://clinicaltrials.gov/ct2/show/NCT00876395Accessed March 21, 2013
   Google Scholar
• Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3) Available from http://clinicaltrials.gov/ct2/show/NCT01007942Accessed March 21, 2013
   Google Scholar
• IrvinWJJrCareyLAWhat is triple-negative breast cancer?Eur J Cancer200844182799280519008097
   PubMed Web of Science ®Google Scholar
• DentRTrudeauMPritchardKITriple-negative breast cancer: clinical features and patterns of recurrenceClin Cancer Res20071315 Pt 14429443417671126
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAGreenMMurrayJOpen label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC (T-FEC) vs the combination of paclitaxel and RAD001 followed by FEC (TR-FEC) in women with triple receptor-negative breast cancer (TNBC)Presented at the American Society of Clinical Oncology Annual MeetingJune 37, 2011Chicago, IL, USA
   Google Scholar
• SinghJSteinSVolmMPhase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancerJ Clin Oncol201230Suppl 15e11529
   Google Scholar
• JerusalemGEllardSFasoloANon-infectious pneumonitis in breast cancer patients treated with Everolimus containing therapy: analysis of five studiesCancer Res200969supp 241115
   Web of Science ®Google Scholar
• Afinitor® (everolimus) tablets for oral administration [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation
   Google Scholar
• Di NicolantonioFArenaSTaberneroJGrossoSDeregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimusJ Clin Invest201012082858286620664172
   PubMed Web of Science ®Google Scholar
• JankuFWhelerJJWestinSNPI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutationsJ Clin Oncol201230877778222271473
   PubMed Web of Science ®Google Scholar
• ChenGYangNWangXIdentification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancerJ Mol Med (Berl)201088994195220508912
   PubMed Web of Science ®Google Scholar